ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Craniopharyngioma Patients
ConditionCraniopharyngioma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age14-80
SponsorDeling Li
About this trial
This study aims to investigate 68Ga-MY6349, an immune-PET tracer targeting trophoblast cell surface antigen 2 (Trop2), for the noninvasive diagnosis of craniopharyngioma in vivo.
Eligibility criteria
Qualifiers
must be able to provide a written informed consent
radiologically presumed and/or histologically confirmed craniopharyngioma scheduled for resection
adequate clinical condition (Karnofsky performance status ≥70)
Disqualifiers
concomitant major central nervous system disorders
severe hepatic or renal dysfunction
history of severe allergy or hypersensitivity to intravenous radiographic contrast agents
claustrophobia precluding PET/CT or MRI examinations
Trial design
Treatments tested in this trial
- 68Ga-MY6349 PET/CT
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Deling Li
Lead sponsor
Beijing Tiantan Hospital
Sponsor institution
Peking Union Medical College Hospital
Collaborator
Source ClinicalTrials.gov